A NOVEL METHOD FOR PRODUCING CUSTOMIZABLE HIGHER QUALITY INJECTABLE INTRA-ARTICULAR PRODUCTS

A novel method for producing customizable injectable intra-articular products with faster processing and scalable manufacturing.

compelling intellectual property for sale or licensing

A technological breakthrough producing higher quality Hyaluronic Acid (HA) for intra-articular products.

Exclusive IP for Exclusive Quality

Inventor Felix Polyak, PhD is an experienced entrepreneur, with relevant scientific publications, conference proceedings and patents to his credit.

Deep Domain Knowledge

Global intra-articular market is projected to grow from $5.0B in 2023 to $9.43B in 2032 with HA segment making up more than 75% of the market.

Multi-billion-dollar-market

Dr. Felix Polyak – Founder of Studio Bioscience

  • Felix Polyak studied Organic and Medicinal Chemistry in Latvia. He graduated from Riga Technical University (MSc) and Institute of Organic Synthesis (PhD).
  • During several years he conducted research in different scientific organizations.
  • Since 1997 he has been working in Montreal, Quebec.
  • Chief Chemist at Theratechnologies (2002–2011).
  • Key contributor to FDA-approved drug Egrifta.
  • Recognized as a leading scientist in hyaluronic acid chemistry.

Dr. Felix Polyak – Founder of Studio Bioscience

Felix Polyak is scientific editor of the comprehensive monograph Hyaluronic Acid: Production, Properties, Application in Biology and Medicine, John Wiley & Sons, 2015.

He is recipient of the prestigious award “Shining Power” (2018) for outstanding achievements in hyaluronic acid chemistry and biology.

In 2019–2020 he invented Acoustic Reactive Crosslinking (ARC), a new technology for crosslinking hyaluronic acid used in dermal fillers and intra-articular injectables.

To accelerate commercialization, he founded Studio BioScience in 2020.